HK$5.03
1.18%
Hong Kong, Oct 02, 03:45 pm HKT. Closed.
ISIN
KYG674111011
Symbol
1477

Ocumension Therapeutics Stock price

HK$5.10
-0.01 0.20% 1M
-3.46 40.42% 6M
-2.30 31.08% YTD
-3.47 40.49% 1Y
-2.55 33.33% 3Y
-12.86 71.60% 5Y
-31.90 86.22% 10Y
-31.90 86.22% 20Y
Hong Kong, Closing price Fri, Oct 02 2026
+0.02 0.30%
ISIN
KYG674111011
Symbol
1477
Industry

Is Ocumension Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$4.1b
Enterprise Value
HK$3.9b
Net debt
positive
Cash
HK$613.6m
Shares outstanding
815.4m
Valuation
P/E
negative
P/S | estimate
3.8 | 3.2
EV/Sales | estimate
3.5 | 3.0
EV/FCF | ex SBC
- | -
P/B
1.0
Financial Health
Equity Ratio
90.0%
Return on Equity
-4.3%
ROCE
-3.3%
ROIC
-3.7%
Debt/Equity
0.1
Financials
Revenue | estimate
HK$1.1b | HK$1.3b
EBITDA
HK$-137.3m
EBIT
HK$-147.1m
Net Income
HK$-146.9m
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
71.8% | 37.6%
EBITDA
53.1%
EBIT
51.7%
Net Income
49.6%
Free Cash Flow
-
Margin
Gross
47.2%
EBITDA
-12.6%
EBIT
-13.5%
Net
-13.4%
Free Cash Flow | ex SBC
- | -
More
EPS
HK$-0.2
FCF per Share
-
Short interest
-
Employees
552
Rev per Employee
HK$1.7m

Ocumension Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Ocumension Therapeutics forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Ocumension Therapeutics forecast:

Buy
75%
Hold
25%

Financial data from Ocumension Therapeutics

Jun '26
+/-
%
1,093 1,093
72% 72%
100%
- Direct Costs 577 577
58% 58%
53%
516 516
90% 90%
47%
- Selling and Administrative Expenses 580 580
19% 19%
53%
- Research and Development Expense 71 71
28% 28%
6%
-137 -137
53% 53%
-13%
- Depreciation and Amortization 9.77 9.77
15% 15%
1%
EBIT (Operating Income) EBIT -147 -147
52% 52%
-13%
Net Profit -147 -147
50% 50%
-13%

In millions HKD.

Don't miss a Thing! We will send you all news about Ocumension Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu and currently employs 552 full-time employees. The company went IPO on 2020-07-10. The products primarily include OT-401 Yutiq fluocinolone intravitreal implant, OT-702 Boyoujing aflibercept intravitreous injection, OT-402 Visudyne, OT- 204 Ou Qin sodium hyaluronate eye drops and OT-305 Betoptic S betaxolol hydrochloride and others. The products are used to treat various anterior and posterior segment eye diseases, such as uveitis, fundus diseases, refractive correction, dry eye disease (DED), glaucoma and conjunctivitis. The firm primarily operates its business in the domestic market.

Head office Cayman Islands
CEO Mr. Liu
Employees 552
Website www.ocumension.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today